SequelSEC

NIKA PHARMACEUTICALS, INC NIKA

Pharmaceutical Preparations · CIK 0001145604 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$0
Fiscal year ended 2024-12-31
Operating income
-$95.79K
Fiscal year ended 2024-12-31
Free cash flow
Unavailable
Fiscal year ended 2024-12-31

NIKA PHARMACEUTICALS, INC (NIKA) reported revenue of $0 and net income of -$95.79K for the fiscal year ended 2024-12-31. This page shows 4 annual periods of income statement, balance sheet and cash flow figures normalized from NIKA PHARMACEUTICALS, INC’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

NIKA PHARMACEUTICALS, INC income by fiscal year, in US dollars, normalized from SEC filings.
Metric2024-12-312023-12-312022-12-312021-12-31
Revenue$0$0$0$0
Cost of revenueUnavailableUnavailableUnavailableUnavailable
Gross profitUnavailableUnavailableUnavailableUnavailable
Operating income-$95.79K-$64.83K-$3.18M-$14.71K
Net income-$95.79K-$64.83K-$3.18M-$14.71K
Research & developmentUnavailableUnavailableUnavailableUnavailable
Weighted-average diluted sharesshares 1.02Bshares 876.09Mshares 723.95Mshares 396.09M
Pretax income-$95.79K-$64.83K-$3.18M-$14.71K
Income tax expenseUnavailableUnavailableUnavailableUnavailable
Diluted EPS$0.00$0.00$0.00$0.00
Selling, general & administrativeUnavailableUnavailableUnavailableUnavailable
General & administrative$35.17K$64.83K$33.72K$14.71K
Selling & marketingUnavailableUnavailableUnavailableUnavailable

Balance

NIKA PHARMACEUTICALS, INC balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2024-12-312023-12-312022-12-312021-12-31
Cash & equivalents$2.08K$19.60K$864$399
Total assets$17.93K$19.60K$864$399
Current assets$17.93K$19.60K$864$399
Total liabilities$239.16K$101.74K$18.18K$24.02K
Current liabilities$239.16K$101.74K$18.18K$10.52K
Total equity incl. NCI-$221.23K-$82.15K-$17.32K-$23.62K
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailable
InventoryUnavailableUnavailableUnavailableUnavailable
Accounts receivableUnavailableUnavailableUnavailableUnavailable
GoodwillUnavailableUnavailableUnavailableUnavailable
Long-term debtUnavailableUnavailableUnavailableUnavailable
Accounts payableUnavailableUnavailableUnavailableUnavailable

Cash flow

NIKA PHARMACEUTICALS, INC cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2024-12-312023-12-312022-12-312021-12-31
Operating cash flow-$154.93K-$64.83K$33.72K$14.71K
Capital expendituresUnavailableUnavailableUnavailableUnavailable
Investing cash flowUnavailableUnavailableUnavailableUnavailable
Financing cash flow$137.42K$83.56K$34.18K$13.50K
Net change in cash-$17.51K$18.73K$465-$1.21K
Stock-based compensationUnavailableUnavailableUnavailableUnavailable
Common dividends paidUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailable
Depreciation & amortizationUnavailableUnavailableUnavailableUnavailable

Derived

NIKA PHARMACEUTICALS, INC derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2024-12-312023-12-312022-12-312021-12-31
Free cash flowUnavailableUnavailableUnavailableUnavailable
Gross marginUnavailableUnavailableUnavailableUnavailable
Operating marginUnavailableUnavailableUnavailableUnavailable
FCF marginUnavailableUnavailableUnavailableUnavailable
SBC / revenueUnavailableUnavailableUnavailableUnavailable
Current ratio0.07x0.19x0.05x0.04x
Revenue YoY growthUnavailableUnavailableUnavailableUnavailable
Net marginUnavailableUnavailableUnavailableUnavailable
R&D / revenueUnavailableUnavailableUnavailableUnavailable
CapEx / revenueUnavailableUnavailableUnavailableUnavailable
Long-term debt / equityUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open NIKA in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-10View SEC filing
10-Q · Filed 2026-05-12View SEC filing
10-K · Filed 2026-03-25View SEC filing
10-Q · Filed 2025-11-07View SEC filing
10-Q · Filed 2025-08-14View SEC filing
10-Q · Filed 2025-05-13View SEC filing

Companies in the same industry

AAGH AARD ABBV ABCL ABEO ABT ABUS ABVC ACAD ACET ACRS ACRV

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.